Levetiracetam Accord 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
amended 
on 
IB/0041/G 
This was an application for a group of variations. 
20/06/2023 
SmPC and PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IA/0040/G 
This was an application for a group of variations. 
07/03/2023 
n/a 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
IB/0039 
C.I.2.a - Change in the SPC, Labelling or PL of a 
20/06/2022 
03/02/2023 
SmPC and PL 
Section 4.8 of the SmPC has been updated to include the 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IA/0038 
B.II.e.7.b - Change in supplier of packaging 
29/04/2022 
n/a 
components or devices (when mentioned in the 
dossier) - Replacement or addition of a supplier 
adverse reaction neuroleptic malignant syndrome (NMS). 
The PL has been updated accordingly. 
Page 2/13 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IA/0037 
A.7 - Administrative change - Deletion of 
10/01/2022 
03/02/2023 
Annex II and 
manufacturing sites 
PL 
IA/0036 
B.III.1.a.2 - Submission of a new/updated or 
29/06/2021 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
IB/0034 
C.I.2.a - Change in the SPC, Labelling or PL of a 
08/06/2021 
21/06/2021 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IAIN/0035 
B.II.b.1.a - Replacement or addition of a 
26/05/2021 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
IA/0033 
B.II.b.4.a - Change in the batch size (including batch 
01/02/2021 
n/a 
size ranges) of the finished product - Up to 10-fold 
compared to the originally approved batch size 
IB/0032/G 
This was an application for a group of variations. 
19/01/2021 
21/06/2021 
SmPC and PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
Page 3/13 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0031 
B.II.b.3.z - Change in the manufacturing process of 
11/01/2021 
n/a 
the finished or intermediate product - Other variation 
IB/0030 
B.I.b.1.z - Change in the specification parameters 
04/12/2020 
n/a 
and/or limits of an AS, starting 
material/intermediate/reagent - Other variation 
IA/0029/G 
This was an application for a group of variations. 
02/07/2020 
n/a 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
IA/0028/G 
This was an application for a group of variations. 
18/03/2020 
n/a 
Page 4/13 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
IB/0027 
C.I.2.a - Change in the SPC, Labelling or PL of a 
04/02/2020 
15/09/2020 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IAIN/0026 
B.II.b.1.a - Replacement or addition of a 
17/09/2019 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
IB/0025 
C.I.2.a - Change in the SPC, Labelling or PL of a 
10/09/2019 
15/09/2020 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
Page 5/13 
 
 
 
 
 
 
 
 
 
 
 
 
 
IAIN/0024 
B.III.1.a.3 - Submission of a new/updated or 
14/08/2019 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - New certificate from a 
new manufacturer (replacement or addition) 
IA/0023 
B.II.b.2.a - Change to importer, batch release 
08/03/2019 
n/a 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
T/0022 
Transfer of Marketing Authorisation 
01/02/2019 
01/03/2019 
SmPC, 
Labelling and 
PL 
IB/0021 
C.I.2.a - Change in the SPC, Labelling or PL of a 
23/10/2018 
01/03/2019 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IAIN/0020/G 
This was an application for a group of variations. 
27/09/2018 
n/a 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.1.b - Replacement or addition of a 
manufacturing site for the FP - Primary packaging 
site 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
Page 6/13 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
control/testing takes place 
IA/0019 
B.III.1.a.4 - Submission of a new/updated or 
31/07/2018 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Deletion of certificates 
(in case multiple certificates exist per material) 
IAIN/0018 
B.II.b.2.c.1 - Change to importer, batch release 
29/06/2018 
01/03/2019 
Annex II and 
arrangements and quality control testing of the FP - 
PL 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
IAIN/0017 
B.II.b.1.a - Replacement or addition of a 
16/11/2017 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
IAIN/0016/G 
This was an application for a group of variations. 
31/08/2017 
n/a 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
B.III.1.a.3 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - New certificate from a 
new manufacturer (replacement or addition) 
IB/0015 
C.I.2.a - Change in the SPC, Labelling or PL of a 
08/12/2016 
16/11/2017 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
Page 7/13 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IAIN/0014/G 
This was an application for a group of variations. 
25/10/2016 
n/a 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
B.III.1.a.3 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - New certificate from a 
new manufacturer (replacement or addition) 
R/0012 
Renewal of the marketing authorisation. 
26/05/2016 
22/07/2016 
SmPC, Annex 
Based on the review of data on quality, safety and efficacy, 
II, Labelling 
the CHMP considered that the benefit-risk balance of 
and PL 
Levetiracetam Accord in the approved indication remains 
favourable and therefore recommended the renewal of the 
marketing authorisation with unlimited validity. 
IA/0013 
B.III.1.a.2 - Submission of a new/updated or 
14/03/2016 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
IB/0011/G 
This was an application for a group of variations. 
08/05/2014 
27/05/2015 
SmPC and PL 
To update the SmPC and package leaflet with the 
tabulated list of adverse reactions in section 4.8 with 
“hyponatraemia” and in section 4 of the PIL including 
“decreased blood sodium concentration”. 
Page 8/13 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To update 4.8 of the SmPC to include ‘drug reaction 
with eosinophilia and systematic symptoms (DRESS)’ 
as a rare adverse drug reaction. The package leaflet 
was updated accordingly. 
In addition Annex II was brought in line with the 
latest QRD version. 
Furthermore minor changes in the FR, FI, LV, PT, PL 
and SV PIL to be in line with the originator product. 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0010 
C.I.2.a - Change in the SPC, Labelling or PL of a 
10/12/2013 
29/01/2014 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
Page 9/13 
 
 
 
 
 
 
 
 
 
 
 
IAIN/0009 
C.I.8.a - Introduction of or changes to a summary of 
30/08/2013 
n/a 
Pharmacovigilance system - Changes in QPPV 
(including contact details) and/or changes in the 
PSMF location 
IAIN/0008 
A.1 - Administrative change - Change in the name 
29/01/2013 
29/01/2014 
SmPC, 
and/or address of the MAH 
Labelling and 
PL 
IAIN/0007 
B.III.1.a.1 - Submission of a new or updated Ph. Eur. 
14/11/2012 
n/a 
Certificate of Suitability to the relevant Ph. Eur. 
Monograph - New certificate from an already 
approved manufacturer 
IB/0006 
C.I.2.a - Change in the SPC, Labelling or PL of a 
11/09/2012 
31/10/2012 
SmPC, Annex 
Following the CHMP adoption of a variation to the Marketing 
generic/hybrid/biosimilar products following 
II, Labelling 
Authorisation of Keppra EMEA/H/C/000277/II/0131 on 19 
assessment of the same change for the reference 
and PL 
April 2012 section 4.8 of the SmPC was updated in order to 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
add ‘panick attack’ as an undesirable effect following the 
cumulative review of the safety data for Keppra. The 
package Leaflet was updated in accordance. In addition, 
editorial changes were made to section 2 and 4.1 of the 
SmPC. Moreover, the description of pancytopenia, 
erythema multiforme, Stevens-Johnsons syndrome and 
toxic epidermal necrolysis in section 4 of the Package 
Leaflet was updated. 
The PI was brought in line with the latest QRD template, 
version 8. 
As requested by EMA minor linguistic amendments for 
languages Estonian, Finnish, French, Hungarian, Icelandic, 
Italian, Lithuanian, Latvian, Maltese, Dutch, Norwegian, 
Polish, Portuguese, Romanian, Slovenian, Slovakian and 
Page 10/13 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IAIN/0004/G 
This was an application for a group of variations. 
18/04/2012 
17/09/2012 
SmPC, 
Swedish were corrected in PI in line with the originato PI. 
Labelling and 
PL 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
Page 11/13 
 
 
 
 
 
 
 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
IAIN/0003 
B.II.e.5.a.1 - Change in pack size of the finished 
18/04/2012 
17/09/2012 
SmPC, 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
Labelling and 
PL 
IB/0002 
Update section 4.8 of the SmPC and section 4 of the 
19/03/2012 
17/09/2012 
SmPC and PL 
PIL as a consequence of the adoption by the CHMP of 
safety variations related to significant modifications 
of the Summary of Product Characteristics due in 
particular to new quality, pre-clinical or 
pharmacovigilance data to the reference medicinal 
product Keppra.  In addition, the MAH has taken this 
opportunity to correct the layout in Annex I and IIIB. 
Page 12/13 
 
 
 
 
 
 
 
 
 
 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
Page 13/13 
 
 
 
 
 
 
 
